Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Citius Pharmaceuticals Inc. (NASDAQ: CTXR).

Full DD Report for CTXR

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTXR)

Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market
CRANFORD, N.J. , March 29, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional ...
Source: PR Newswire
Date: March, 29 2018 08:00
Pretenders And Ghosts: Stealth Promotion Network Exploits Financial Sites To Tout Stocks
Meet George Ronan. Again and again and again. The George Ronan who talked up a succession of small public companies at Seeking Alpha described himself as a university lecturer in the United Kingdom with an interest in technology stocks. The George Ronan whose articles appear on MarketEx...
Source: SeekingAlpha
Date: March, 07 2018 07:45
Citius Reports Progress in Hemorroid Treatment Program
CRANFORD, N.J. , March 6, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that the Company is selecting a higher potency corticosteroid in its steroid/anesthetic topical formulation program for the t...
Source: PR Newswire
Date: March, 06 2018 08:00
Citius Pharma commences late-stage study of Mino-Lok in catheter-related bloodstream infections
Enrollment is underway in a 700-subject Phase 3 clinical trial evaluating Citius Pharmaceuticals' ( OTCQB:CTXR ) Mino-Lok in patients with catheter-related bacteremias (bloodstream infections). More news on: Citius Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Re...
Source: SeekingAlpha
Date: February, 16 2018 08:57
Citius Announces Enrollment Of First Patient In The Mino-Lok(TM) Phase 3 Trial
CRANFORD, N.J. , Feb. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that yesterday the first patient was randomized into the ...
Source: PR Newswire
Date: February, 15 2018 08:00
Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias
CRANFORD, N.J. , Feb. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, published the proceedings of a roundtable of experts today, entitle...
Source: PR Newswire
Date: February, 13 2018 08:00
Midday Gainers / Losers (2/9/2018)
Gainers: INPX +32% . AOI +28% . CGG +24% . WAIR +24% . IO +16% . MOBL +16% . UIS +14% . PCYG +15% . AQXP +14% . MCFT +13% . More news on: Inpixon, Alliance One International, Inc., CGG, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: February, 09 2018 12:46
Daily Insider Ratings Round Up 1/8/18: VSI, CNBKA, MSF
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: January, 10 2018 09:30
Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback
Analysis of top Seeking Alpha coverage: Aradigm Today we will discuss the much-anticipated FDA briefing documents for Aradaigm’s ( ARDM ) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11 th . Following the release of the docu...
Source: SeekingAlpha
Date: January, 10 2018 01:14
Citius Pharmaceuticals to Present at Biotech Showcase(TM) 2018
CRANFORD, N.J. , Jan. 4, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it will be presenting at the Biotech Showcase™ 2018. The c...
Source: PR Newswire
Date: January, 04 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-182.302.322.32522.266,632
2018-05-172.302.322.32522.266,632

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-133,20912,09326.5360Cover
2018-06-122,7974,12967.7404Short
2018-06-114,63411,81939.2081Short
2018-06-081121,5377.2869Cover
2018-06-071,5983,34847.7300Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTXR.


About Citius Pharmaceuticals Inc. (NASDAQ: CTXR)

Logo for Citius Pharmaceuticals Inc. (NASDAQ: CTXR)

lt p gt Citius Pharmaceuticals, Inc., company was founded in and is based in Cranford, NJ. Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. lt /p gt

 

Contact Information

 

 

Current Management

  • Leonard Mazur / Secretary
  • Myron Holubiak / CEO, President
    • Myron Holubiak is the President, Chief Executive Officer and a Director of the Company. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. Roche , a major researchbased pharmaceutical company, from December to August . Prior to that, he held sales and marketing positions at Roche during his year tenure. Since July , Mr. Holubiak has served as a member of the board of directors of Assembly Biosciences, Inc. Assembly Nasdaq: ASMB and its predecessor Ventrus Biosciences, Inc. Ventrus . Assembly is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection HBV and C. difficileassociated diarrhea CDAD . Ventrus developed treatment for hemorrhoids, however, phase clinical trials of their compound which was a new molecular entity and not previously approved HC/Lido failed to demonstrate efficacy. After Ventrus merger with Assembly, this program was discontinued. In March, , Mr. Holubiak founded LeonardMeron Biosciences, Inc. LMB , the Company s whollyowned subsidiary, and he served as the Chief Executive Officer and President of LMB until March, . In addition, Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh.
  • Leonard Mazur / Executive Chairman
  • Suren Dutia /
  • Dr. Eugene Holuka /
  • Dr. William Kane /
  • Howard Safir /
  • Carol Webb /

Current Share Structure

  • Market Cap: $32,144,352 - 03/09/2018
  • Authorized: 200,000,000 - 03/01/2018
  • Issue and Outstanding: 9,982,718 - 03/01/2018

 


Recent Filings from (NASDAQ: CTXR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 27 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 27 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 26 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 26 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 20 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 20 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 11 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 11 2018

 

 


Daily Technical Chart for (NASDAQ: CTXR)

Daily Technical Chart for (NASDAQ: CTXR)


Stay tuned for daily updates and more on (NASDAQ: CTXR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTXR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTXR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CTXR and does not buy, sell, or trade any shares of CTXR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/